World Journal of Gastroenterology · 2017 · 47 citations · 14 references
MedicinePharmacologyPharmacotherapyClinical PharmacologyGastroenterologyGastrointestinal PharmacotherapyGastrointestinal PharmacologyHelicobacter Pylori Eradication TherapyPeptic Ulcer PharmacotherapyConcomitant TherapyEradicationFirst-line Eradication TherapyHelicobacter Pylori EradicationHelicobacter Pylori InfectionProton Pump InhibitionSerious Adverse EventsVonoprazan-based Therapy
AIM: ). METHODS: -positive patients with associated gastrointestinal diseases from April 2014 to December 2015 at Hattori Clinic, Japan. The primary endpoint was the eradication rate, which was assessed with a full analysis set. The secondary endpoints were adverse events and related factors. RESULTS: = 0.054), although the vonoprazan group exhibited a wider range of adverse events. Vonoprazan-based triple therapy was highly effective as a second-line treatment, with an eradication rate similar to that of PPI-based therapy. CONCLUSION: therapy, particularly for smokers. However, caution is required due to possible adverse events.
14
<i>Helicobacter pylori</i> Infection and the Development of Gastric Cancer
Naomi Uemura, Shiro Okamoto, Soichiro Yamamoto et al. · New England Journal of Medicine · 2001 · 4.5K citations · Full text
Medicine, Microbiology, Oncology +15